Pyrrolidine Derivatives as PPAR Agonists for NASH
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nonalcoholic steatohepatitis (NASH) and related conditions lack effective FDA-approved medications, and existing PPAR agonists have limitations in activity and selectivity.
Innovation Solution
Development of pyrrolidine derivatives as PPAR agonists, specifically represented by Formula (I) and its pharmaceutically acceptable salts, which are designed to treat NASH, insulin resistance, and other PPAR receptor-associated disorders with enhanced activity and selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional PPAR agonists are used, then some therapeutic effect is achieved, but activity and selectivity are insufficient
Solution Approach 1:
The patent modifies the chemical structure of PPAR agonists by changing parameters such as the pyrrolidine ring substituents (R1, R2, R3), the heteroatom (X), and the side chain configurations (R4, R5, n, L1-L4) to optimize both activity and selectivity. This systematic parameter variation allows tuning of the compound's interaction with PPAR receptors to achieve superior therapeutic efficacy and selectivity compared to conventional agonists.
Solution Approach 2:
The patent introduces specific local structural features at different positions of the molecule (R1 at position 1, R2 and R3 at positions 2 and 3 of the pyrrolidine ring, R4 and R5 on side chains) to enhance interaction with specific regions of the PPAR receptor binding site. Each substituent is designed to provide local chemical properties (hydrophobicity, hydrogen bonding capability, steric bulk) that improve binding affinity and selectivity for the target receptor subtype.
2Adaptability or versatility
If no FDA-approved medications are used, then treatment options are limited, but existing treatments lack effectiveness for NASH
Solution Approach 1:
The patent segments the broad category of PPAR agonists into more specific subclasses based on the pyrrolidine core structure with defined substituent patterns. This segmentation allows for the development of compounds with tailored profiles for specific indications (NASH, insulin resistance, dyslipidemia, etc.), providing both diverse treatment options and targeted effectiveness for different metabolic disorders.
Data Source
AI summary
The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholgangitis, dyslipidenmia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.